Mengyang Pharmaceutical's world's first oral cardioprotective agent (reducing doxorubicin cardiotoxicity) DH001 completed the first subject dosing in China


Shanghai, China, January 4, 2021 – Mengyang Pharmaceutical Co., Ltd. announced that it has completed the dosing of the first patient in the clinical trial of DH001, a class 1 new small molecule chemical drug independently developed by its self-developed small molecule chemical drug, registered and conducted in China.

This study (LXC2008DH001) is a Phase I clinical study conducted in healthy adult subjects in China to evaluate the safety, tolerability and pharmacokinetics of DH001 after single and multiple oral administrations in healthy adult subjects.

DH001 is an effective monomer extracted and purified from traditional Chinese medicine, which can reduce the incidence and severity of cardiotoxicity caused by doxorubicin, and is suitable for patients treated with doxorubicin.

Dr. Zhang Min, Chairman of Mengyang Pharmaceutical, said: With the progress of tumor treatment methods and new drug research and development, the survival cycle of cancer patients will continue to be extended, the trend of "chronic disease" of tumors is obvious, and "survival with tumors" will become the norm. The related diseases caused by tumor treatment will seriously affect the treatment of patients and reduce the quality of life of patients, and even endanger their lives. Therefore, the detection and treatment of these related diseases have received more and more attention. The delayed cardiotoxicity caused by doxorubicin is particularly serious, and patients often develop cardiotoxicity after 1, 5 or even 10 years after treatment, causing great distress to patients. DH001, like "artemisinin", is an active monomer discovered from traditional Chinese medicine, which can effectively prevent and treat cardiotoxicity caused by doxorubicin drugs. Today's dosing of the first patient is an important milestone in the development of DH001, and we look forward to the successful progress of this study and the early benefit of Chinese patients."

Mengyang Pharmaceutical Co., Ltd. is committed to excavating the treasures of traditional medicine in the motherland, developing the classic prescriptions of famous and old Chinese medicine and the active ingredients derived from natural medicines into new medicines, protecting China's intangible cultural heritage and benefiting mankind. The company adheres to the industry to serve the country and innovate, in today's increasingly powerful motherland, when the people of the whole country are working hard to realize the Chinese dream of the great rejuvenation of the Chinese nation, Mengyang Pharmaceutical, as a responsible and responsible national pharmaceutical company, will do its best to realize the dream of promoting the motherland's medicine and bringing health to patients!

Hot news

Service hotline


Address:3 Fuyao Yi Lu, Doudao District, Jingmen City, Hubei Province, China

COPYRIGHT© 2022 Hubei Mengyang Pharmaceutical Co., LTD. All Rights Reserved E ICP 11014915; Internet Drug Information Service Certificate No. : (E) - Non-business -2016-0032

Technical Support: SUMA